

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities of the Company.

*This announcement is not for distribution, directly or indirectly, in or into the United States. This announcement and the information contained in this announcement do not constitute or form part of an offer to sell securities in the United States. Securities may not be offered or sold in the United States unless registered pursuant to the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), or pursuant to an applicable exemption from such registration requirement. The securities referred to in this announcement have not been and will not be registered under the Securities Act and no public offering of securities will be made in the United States. No money, securities or other consideration is being solicited by this announcement or the information contained in this announcement and, if sent in response to this announcement or the information contained in this announcement, will not be accepted.*



微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

**COMPLETION OF REDEMPTION OF
THE US\$700 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026**

(Stock Code: 40720)

This announcement is made by MicroPort Scientific Corporation (the “**Company**”) pursuant to Rule 37.50(b) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the announcements of the Company dated 11 June 2021, 15 June 2021, 5 December 2023, 19 December 2023, 5 April 2024 and 28 May 2024 in relation to, among other things, the zero coupon convertible bonds due 2026 in the aggregate principal amount of US\$700 million (ISIN: XS2342920050) (the “**2026 Convertible Bonds**”) issued by the Company (collectively, the “**Announcements**”). Unless the context otherwise requires, capitalised words and expressions used herein shall have the same meanings as defined in the Announcements.

Pursuant to the condition 8(e) (*Redemption at the Option of the Bondholders*) of the terms and conditions of the 2026 Convertible Bonds set out in the offering circular in relation to the 2026 Convertible Bonds dated 8 June 2021, the holder of each 2026 Convertible Bond can exercise the right, at such holder's option, to require the Company to redeem all or some only of the 2026 Convertible Bonds of such holder on 11 June 2024 (the "**Put Option Date**"). Notices of redemption have been served on the Company requiring the Company to redeem all the outstanding 2026 Convertible Bonds (the "**Early Redemption**"), and such Early Redemption has been completed.

As of the date of this announcement, all of the 2026 Convertible Bonds (in the aggregate principal amount of US\$700 million) have been redeemed and cancelled and there are no outstanding 2026 Convertible Bonds in issue. Accordingly, the Company has made an application to The Stock Exchange of Hong Kong Limited for the withdrawal of the listing of the 2026 Convertible Bonds. Such withdrawal of listing is expected to be effective upon the close of business on 20 June 2024.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 12 June 2024

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only.*